Author:
Ingrasciotta Ylenia,Giorgianni Francesco,Bolcato Jenny,Chinellato Alessandro,Pirolo Roberta,Tari Daniele Ugo,Troncone Chiara,Fontana Andrea,Ientile Valentina,Gini Rosa,Santoro Domenico,Santarpia Mariacarmela,Genazzani Armando,Uomo Ilaria,Pastorello Maurizio,Addario Walter Sebastiano Pollina,Scondotto Salvatore,Cananzi Pasquale,Caputi Achille Patrizio,Trifirò Gianluca
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference33 articles.
1. Blackstone EA, Fuhr JP. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–78.
2. Ventola CL. Biosimilars: part 1. Proposed regulatory criteria for FDA approval. Pharm Ther. 2013;38(5):270–87.
3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP): guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf .
4. Agenzia Italiana del Farmaco (AIFA). Position paper sui farmaci biosimilari (28/05/2013). Available from: http://www.agenziafarmaco.gov.it/sites/default/files/AIFA_POSITION_PAPER_FARMACI_BIOSIMILARI.pdf .
5. Genazzani AA, Biggio G, Caputi AP, et al. Biosimilar drugs: concerns and opportunities. Biodrugs. 2007;21:351–6.
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献